ArticleStudies in health technology and informatics2025
Type 2 Diabetes Subtyping via Phenotype and Genotype Co-Learning.
Article in Studies in health technology and informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Interpreting and subtyping type 2 diabetes (T2D) is challenging yet essential for achieving fine-grained pathophysiological insights and precise clinical stratification. Previous studies have primarily relied on a small number of pre-selected risk factors and biomarkers, neglecting the integration of multimodality data (e.g., phenotypic and genetic features) for more comprehensive analyses. In this study, we select a cohort of 42,256 participants from the National Institutes of Health's All of Us Research Program, where our hypergraph framework achieves an AUROC of 89.64% on predicting T2D when integrating phenotypic and genetic features. The proposed pipeline performs subtyping by clustering clinical concepts, genetic variants, and individuals in an end-to-end manner. Further analysis using genetic risk scores reveals distinct genetic profiles between T2D subtypes and highlights the potential applications of our solution in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.